Neurological complications after orthotopic liver transplantation

Digestive and Liver Disease

Volumn 39, Issue 8, 2007, Pages 740-747

  Amodio, P ^a   Biancardi, A ^a   Montagnese, S ^a   Angeli, P ^a   Iannizzi, P ^a   Cillo, U ^a   D'Amico, D ^a   Gatta, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Encephalopathy; Immunosuppressants; Liver cirrhosis; Liver transplantation; Neurological complication; Neurotoxicity; OLTx

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS;

ACUTE PSYCHOSIS; ARTICLE; ASEPTIC MENINGITIS; BEHAVIOR DISORDER; BRAIN DISEASE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN TOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL NERVOUS SYSTEM TUMOR; CENTRAL PONTINE MYELINOLYSIS; CEREBELLUM DISEASE; CLINICAL FEATURE; CONFUSION; CONSCIOUSNESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; LIVER TRANSPLANTATION; MANIA; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC ENCEPHALOPATHY; MOOD CHANGE; MUSCLE WEAKNESS; MYOCLONUS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROMUSCULAR DISEASE; NEUROTOXICITY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PERSISTENT VEGETATIVE STATE; POSTOPERATIVE COMPLICATION; PREVALENCE; PSYCHOSIS; RADICULOPATHY; RESTLESS LEGS SYNDROME; RIGIDITY; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SPINAL CORD ISCHEMIA; TREMOR;

HUMANS; ITALY; LIVER FAILURE; LIVER TRANSPLANTATION; MORBIDITY; NERVOUS SYSTEM DISEASES; SURVIVAL RATE; TRANSPLANTATION, HETEROTOPIC;

EID: 34447265980     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.05.004     Document Type: Article

References (104)

1. Wang W.L., Yang Z.F., Lo C.M., Liu C.L., and Fan S.T. Intracerebral hemorrhage after liver transplantation. Liver Transpl 6 (2000) 345-348
2. Adams D.H., Ponsford S., Gunson B., Boon A., Honigsberger L., Williams A., et al. Neurological complications following liver transplantation. Lancet 1 (1987) 949-951
3. Burkhalter E.L., Starzl T.E., and Van Thiel D.H. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. J Hepatol 21 (1994) 572-577
4. Guarino M. Immunosupprressive therapy. Gastroenterol Int Congress Proc 12 (1999) 140-145
5. Casanova B. Neurological complications after liver transplant. Gastroenterol Int Congress Proc 12 (1999) 135-139
6. Bronster D.J., Emre S., Boccagni P., Sheiner P.A., Schwartz M.E., and Miller C.M. Central nervous system complications in liver transplant recipients-incidence, timing, and long-term follow-up. Clin Transplant 14 (2000) 1-7
7. Lewis M.B., and Howdle P.D. Neurologic complications of liver transplantation in adults. Neurology 61 (2003) 1174-1178
8. Wijdicks E.F., Wiesner R.H., and Krom R.A. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 45 (1995) 1962-1964
9. Fryer J.P., Fortier M.V., Metrakos P., Verran D.J., Asfar S.K., Pelz D.M., et al. Central pontine myelinolysis and cyclosporine neurotoxicity following liver transplantation. Transplantation 61 (1996) 658-661
10. Yu J., Zheng S.S., Liang T.B., Shen Y., Wang W.L., and Ke Q.H. Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol 10 (2004) 2540-2543
11. Saner F.H., Sotiropoulos G.C., Gu Y., Paul A., Radtke A., Gensicke J., et al. Severe neurological events following liver transplantation. Arch Med Res 38 (2007) 75-79
12. Eidelman B.H., Abu-Elmagd K., Wilson J., Fung J.J., Alessiani M., Jain A., et al. Neurologic complications of FK 506. Transplant Proc 23 (1991) 3175-3178
13. Bronster D.J., Chodoff L., Yonover P., and Sheiner P.A. Cyclosporine levels in cerebrospinal fluid after liver transplantation. Transplantation 68 (1999) 1410-1413
14. Beresford T.P. Neuropsychiatric complications of liver and other solid organ transplantation. Liver Transpl 7 (2001) S36-S45
15. Bronster D.J., Emre S., Mor E., Sheiner P., Miller C.M., and Schwartz M.E. Neurologic complications of orthotopic liver transplantation. Mt Sinai J Med 61 (1994) 63-69
16. Baliga P., Merion R.M., Turcotte J.G., Ham J.M., Henley K.S., Lucey M.R., et al. Preoperative risk factor assessment in liver transplantation. Surgery 112 (1992) 704-710
17. Bechstein W.O. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 13 (2000) 313-326
18. Di Martini A., Pajer K., Trzepacz P., Fung J., Starzl T., and Tringali R. Psychiatric morbidity in liver transplant patients. Transplant Proc 23 (1991) 3179-3180
19. Pujol A., Graus F., Rimola A., Beltran J., Garcia-Valdecasas J.C., Navasa M., et al. Predictive factors of in-hospital CNS complications following liver transplantation. Neurology 44 (1994) 1226-1230
20. Kaplan P.E., Clinchot D.M., and Arnett J.A. Cognitive deficits after hepatic transplantation: relevance to the rehabilitation potential. Brain Inj 10 (1996) 599-607
21. Bronster D.J., Gurkan A., Buchsbaum M.S., and Emre S. Tacrolimus-associated mutism after orthotopic liver transplantation. Transplantation 70 (2000) 979-982
22. Mueller A.R., Platz K.P., Bechstein W.O., Schattenfroh N., Stoltenburg-Didinger G., Blumhardt G., et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58 (1994) 155-170
23. Stracciari A., and Guarino M. Neuropsychiatric complications of liver transplantation. Metab Brain Dis 16 (2001) 3-11
24. Philips B.J., Armstrong I.R., Pollock A., and Lee A. Cerebral blood flow and metabolism in patients with chronic liver disease undergoing orthotopic liver transplantation. Hepatology 27 (1998) 369-376
25. Christe W. Neurological disorders in liver and kidney transplant recipients. Transplant Proc 26 (1994) 3175-3176
26. Eidelman B.H. Neurological complications of immunosuppressive agents. Gastroenterol Int Congress Proc 12 (1999) 128-134
27. Wijdicks E.F., Litchy W.J., Wiesner R.H., and Krom R.A. Neuromuscular complications associated with liver transplantation. Muscle Nerve 19 (1996) 696-700
28. Bronster D.J., Yonover P., Stein J., Scelsa S.N., Miller C.M., and Sheiner P.A. Demyelinating sensorimotor polyneuropathy after administration of FK506. Transplantation 59 (1995) 1066-1068
29. Ardizzone G., Arrigo A., Schellino M.M., Stratta C., Valzan S., Skurzak S., et al. Neurological complications of liver cirrhosis and orthotopic liver transplant. Transplant Proc 38 (2006) 789-792
30. Saner F., Gu Y., Minouchehr S., Ilker K., Fruhauf N.R., Paul A., et al. Neurological complications after cadaveric and living donor liver transplantation. J Neurol 253 (2006) 612-617
31. Estol C.J., Lopez O., Brenner R.P., and Martinez A.J. Seizures after liver transplantation: a clinicopathologic study. Neurology 39 (1989) 1297-1301
32. Vogt D.P., Lederman R.J., Carey W.D., and Broughan T.A. Neurologic complications of liver transplantation. Transplantation 45 (1988) 1057-1061
33. Singh N., Bonham A., and Fukui M. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. Transplantation 69 (2000) 467-472
34. Dawson T.M. Immunosuppressants, immunophilins, and the nervous system. Ann Neurol 40 (1996) 559-560
35. Hinchey J., Chaves C., Appignani B., Breen J., Pao L., Wang A., et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334 (1996) 494-500
36. Small S.L., Fukui M.B., Bramblett G.T., and Eidelman B.H. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506). Ann Neurol 40 (1996) 575-580
37. Boon A.P., Adams D.H., Buckels J.A., and McMaster P. Neuropathological findings in autopsies after liver transplantation. Transplant Proc 23 (1991) 1471-1472
38. Wszolek Z.K., McComb R.D., Pfeiffer R.F., Steg R.E., Wood R.P., Shaw Jr. B.W., et al. Pontine and extrapontine myelinolysis following liver transplantation. Relationship to serum sodium. Transplantation 48 (1989) 1006-1012
39. Buis C.I., and Wijdicks E.F. Serial magnetic resonance imaging of central pontine myelinolysis. Liver Transpl 8 (2002) 643-645
40. Lampl C., and Yazdi K. Central pontine myelinolysis. Eur Neurol 47 (2002) 3-10
41. Laureno R., and Karp B.I. Pontine and extrapontine myelinolysis following rapid correction of hyponatraemia. Lancet 1 (1988) 1439-1441
42. Gijtenbeek J.M., van den Bent M.J., and Vecht C.J. Cyclosporine neurotoxicity: a review. J Neurol 246 (1999) 339-346
43. Wijdicks E.F. Neurotoxicity of immunosuppressive drugs. Liver Transpl 7 (2001) 937-942
44. Mueller A.R., Platz K.P., Christe W., Bechstein W.O., Blumhardt G., and Neuhaus P. Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. Transplant Proc 26 (1994) 3131-3132
45. Platz K.P., Mueller A.R., Bechstein W.O., Blumhardt G., and Neuhaus P. Causes of death following liver transplantation in FK 506- and cyclosporine-treated patients. Transplant Proc 26 (1994) 3133-3134
46. Larsen F.S., Ranek L., Hansen B.A., and Kirkegaard P. Chronic portosystemic hepatic encephalopathy refractory to medical treatment successfully reversed by liver transplantation. Transpl Int 8 (1995) 246-247
47. Gabriel A., Muller C., Tuchy G., Hackl W., and Zimpfer M. Reperfusion during orthotopic liver transplantation: analysis of right ventricular dynamics. Transplant Proc 25 (1993) 1811-1812
48. Aggarwal S., Kang Y., Freeman J.A., Fortunato F.L., and Pinsky M.R. Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. Transplant Proc 19 (1987) 54-55
49. Ward R., Jones D., and Haponik E.F. Paradoxical embolism. An underrecognized problem. Chest 108 (1995) 549-558
50. Di Chiro G., and Wener L. Angiography of the spinal cord. A review of contemporary techniques and applications. J Neurosurg 39 (1973) 1-29
51. Goss J.A., Seu P., Shackleton C.R., and Busuttil R.W. Lower extremity paralysis after use of the supraceliac aorta for hepatic arterial reconstruction of the transplanted liver. Transplantation 63 (1997) 163-164
52. Lama C., Ramos E., Figueras J., Rafecas A., Fabregat J., Torras J., et al. Causes of mortality after liver transplantation: period of main incidence. Transplant Proc 34 (2002) 287-289
53. Martinez A.J., Estol C., and Faris A.A. Neurologic complications of liver transplantation. Neurol Clin 6 (1988) 327-348
54. Pizzolato G.P., Sztajzel R., Burkhardt K., Megret M., and Borisch B. Cerebral vasculitis during FK 506 treatment in a liver transplant patient. Neurology 50 (1998) 1154-1157
55. Pless M., and Zivkovic S.A. Neurologic complications of transplantation. Neurology 8 (2002) 107-120
56. Power C., Poland S.D., Kassim K.H., Kaufmann J.C., and Rice G.P. Encephalopathy in liver transplantation: neuropathology and CMV infection. Can J Neurol Sci 17 (1990) 378-381
57. Power C., Poland S.D., Kassim K.H., and Kaufmann J.C.E. Encephalopathy in liver transplantation: neurophatology and CMV infection. Can J Neurol Sci 17 (1990) 378-381
58. Penn I. Posttransplant malignancies. Transplant Proc 31 (1999) 1260-1262
59. Cohen J.I. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 70 (1991) 137-160
60. Patchell R.A. Primary central nervous system lymphoma in the transplant patient. Neurol Clin 6 (1988) 297-303
61. Braun K.P., Glander P., Hambach P., Bohler T., Waiser J., Mai I., et al. Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. Transplant Proc 34 (2002) 1745-1747
62. Daly I., Jain A., Reyes J., and Fung J. Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. Transplant Proc 34 (2002) 1503
63. McDiarmid S.V. Mycophenolate mofetil as induction therapy after liver transplantation. Liver Transpl Surg 5 (1999) S85-S89
64. Paul L.C. Overview of side effects of immunosuppressive therapy. Transplant Proc 33 (2001) 2089-2091
65. Fessler R.G., Johnson D.L., Brown F.D., Erickson R.K., Reid S.A., and Kranzler L. Epidural lipomatosis in steroid-treated patients. Spine 17 (1992) 183-188
66. Adair J.C., Woodley S.L., O'Connell J.B., Call G.K., and Baringer J.R. Aseptic meningitis following cardiac transplantation: clinical characteristics and relationship to immunosuppressive regimen. Neurology 41 (1991) 249-252
67. Coleman A.E., and Norman D.J. OKT3 encephalopathy. Ann Neurol 28 (1990) 837-838
68. Dumont F.J. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 7 (2000) 731-748
69. Kochi S., Takanaga H., Matsuo H., Naito M., Tsuruo T., and Sawada Y. Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. Eur J Pharmacol 372 (1999) 287-295
70. Kahan B.D., and Ghobrial R. Immunosuppressive agents. Surg Clin North Am 74 (1994) 1029-1054
71. Sigal N.H., and Dumont F.J. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10 (1992) 519-560
72. de Mattos A.M., Olyaei A.J., and Bennett W.M. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 28 (1996) 631-667
73. Morris R.E. Mechanisms of action of new immunosuppressive drugs. Kidney Int Suppl 53 (1996) S26-S38
74. Peters D.H., Fitton A., Plosker G.L., and Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46 (1993) 746-794
75. Steiner J.P., Dawson T.M., Fotuhi M., Glatt C.E., Snowman A.M., Cohen N., et al. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 358 (1992) 584-587
76. Brazelton T.R., and Morris R.E. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 8 (1996) 710-720
77. Forgacs B., Merhav H.J., Lappin J., and Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 37 (2005) 1912-1914
78. Fung J., Kelly D., Kadry Z., Patel-Tom K., and Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl 11 (2005) 267-280
79. Neuhaus P., Klupp J., and Langrehr J.M. mTOR inhibitors: an overview. Liver Transpl 7 (2001) 473-484
80. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35 (2003) 7S-14S
81. Kochi S., Takanaga H., Matsuo H., Ohtani H., Naito M., Tsuruo T., et al. Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin A and tacrolimus. Life Sci 66 (2000) 2255-2260
82. McDonald J.W., Goldberg M.P., Gwag B.J., Chi S.I., and Choi D.W. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann Neurol 40 (1996) 750-758
83. Diaz-Ruiz A., Vergara P., Perez-Severiano F., Segovia J., Guizar-Sahagun G., Ibarra A., et al. Cyclosporin-A inhibits constitutive nitric oxide synthase activity and neuronal and endothelial nitric oxide synthase expressions after spinal cord injury in rats. Neurochem Res 30 (2005) 245-251
84. Morioka M., Hamada J., Ushio Y., and Miyamoto E. Potential role of calcineurin for brain ischemia and traumatic injury. Prog Neurobiol 58 (1999) 1-30
85. Gold B.G. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Invest Drugs 9 (2000) 2331-2342
86. Spencer C.M., Goa K.L., and Gillis J.C. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54 (1997) 925-975
87. Taylor A.L., Watson C.J., and Bradley J.A. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 56 (2005) 23-46
88. Thompson C.B., June C.H., Sullivan K.M., and Thomas E.D. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 2 (1984) 1116-1120
89. Wilkinson A., and Pham P.T. Kidney dysfunction in the recipients of liver transplants. Liver Transpl 11 (2005) S47-S51
90. Gottrand F., Largilliere C., and Farriaux J.P. Cyclosporine neurotoxicity. N Engl J Med 324 (1991) 1744-1745
91. Truwit C.L., Denaro C.P., Lake J.R., and DeMarco T. MR imaging of reversible cyclosporin A-induced neurotoxicity. AJNR Am J Neuroradiol 12 (1991) 651-659
92. Dohgu S., Kataoka Y., Ikesue H., Naito M., Tsuruo T., Oishi R., et al. Involvement of glial cells in cyclosporine-increased permeability of brain endothelial cells. Cell Mol Neurobiol 20 (2000) 781-786
93. Tsuji A., Tamai I., Sakata A., Tenda Y., and Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 46 (1993) 1096-1099
94. Stoltenburg-Didinger G., and Boegner F. Glia toxicity in dissociation cell cultures induced by cyclosporine. Neurotoxicology 13 (1992) 179-184
95. Lieberman D.N., and Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 369 (1994) 235-239
96. Lyson T., Ermel L.D., Belshaw P.J., Alberg D.G., Schreiber S.L., and Victor R.G. Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Circ Res 73 (1993) 596-602
97. Sander M., Lyson T., Thomas G.D., and Victor R.G. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 9 (1996) 121S-138S
98. Martina M., Mozrzymas J.W., Boddeke H.W., and Cherubini E. The calcineurin inhibitor cyclosporin A-cyclophilin A complex reduces desensitization of GABAA-mediated responses in acutely dissociated rat hippocampal neurons. Neurosci Lett 215 (1996) 95-98
99. Gold B.G. FK506 and the role of immunophilins in nerve regeneration. Mol Neurobiol 15 (1997) 285-306
100. Bennett P.C., Singaretnam L.G., Zhao W.Q., Lawen A., and Ng K.T. Peptidyl-prolyl-cis/trans-isomerase activity may be necessary for memory formation. FEBS Lett 431 (1998) 386-390
101. Shuto H., Kataoka Y., Fujisaki K., Nakao T., Sueyasu M., Miura I., et al. Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci 65 (1999) 879-887
102. Shuto H., Kataoka Y., Kanaya A., Matsunaga K., Sueyasu M., and Oishi R. Enhancement of serotonergic neural activity contributes to cyclosporine-induced tremors in mice. Eur J Pharmacol 341 (1998) 33-37
103. Craven J.L. Cyclosporine-associated organic mental disorders in liver transplant recipients. Psychosomatics 32 (1991) 94-102
104. de Groen P.C., Aksamit A.J., Rakela J., Forbes G.S., and Krom R.A. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 317 (1987) 861-866